IGF2BP1 and cancer: Therapies directed at inhibiting Igf2bp1 function constitute a potentially powerful approach for fighting cancer, given the correlation between elevated Igf2bp1 expression and poor clinical outcomes [11,44], the activation of Igf2bp1 in a wide variety of cancers [1], and the effectiveness of preventing metastasis when Igf2bp1 activity is reduced [3,44–46].